HUYA Bioscience International Announces the Successful Completion of Phase 1 Trial of HBI-3000

Phase 2 trial will test the unique multi-channel ion blocker in acute atrial fibrillation

San Diego, CA, USA – February 28, 2020 HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, has presented the results of a Phase I study of HBI-3000, a novel drug for cardioversion of atrial fibrillation (AF).

SVUS Women in Business and the Professions World Award^® for Excellence in Industry

Woman of the Year – Pharmaceuticals and Biotech

Mireille Gillings, PhD, Hon DSc, CEO & Executive Chair, HUYABIO International, San Diego, CA

Stevie Awards for Women in Business – Silver Stevie^® Award

Female Executive of the Year – Business Products – 11 to 2,500 Employees

Suzanne Romano, PhD, Senior Vice President, Product Evaluation & Early Stage Development

Business Intelligence Group Awards for Industry Leaders

Entrepreneur of the Year

Mireille Gillings, PhD, Hon DSc, CEO & Executive Chair, HUYABIO International, San Diego, CA

Small Business of the Year

HUYABIO International

Executive of the Year

Gloria Tsi-Yie Lee, MD, PhD, Chief Medical Officer

Small Business Executive of the Year

Curtis Tyree, PhD, Senior Vice President, Strategic Planning

17th Annual Stevie® International Business Awards^® – Silver Award

Woman of the Year – Pharmaceuticals

Yung-Chih Wang, PhD, Senior Vice President, Corporate Development, China